Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 3/20 | 0.46 |
| ▸ | FABP4 | P15090 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.45 |
| ▸ | CMKLR1 | Q99788 | 3/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131831 | 0.90 | FABP3 (0.43) | FABP3FABP4MDM2CMKLR1BTK | |
| SCHEMBL1131074 | 0.85 | HRH3 (0.45) | FABP3FABP4MDM2CMKLR1BTK | |
| SCHEMBL1132134 | 0.83 | MDM2 (0.63) | FABP3FABP4MDM2CMKLR1BTK | |
| SCHEMBL1131895 | 0.80 | HRH3 (0.48) | FABP3FABP4MDM2CMKLR1BTK | |
| SCHEMBL1131968 | 0.80 | FABP3 (0.54) | FABP3FABP4FFAR1MDM2CMKLR1 | |
| SCHEMBL1132018 | 0.79 | FABP3 (0.46) | FABP3FABP4MDM2CMKLR1BTK | |
| SCHEMBL1131599 | 0.79 | FABP3 (0.46) | FABP3FABP4MDM2CMKLR1BTK | |
| SCHEMBL1131603 | 0.79 | FABP3 (0.46) | FABP3FABP4MDM2CMKLR1BTK | |
| SCHEMBL4230947 | 0.78 | CMKLR1 (0.58) | CMKLR1 | |
| SCHEMBL1131946 | 0.78 | FAAH (0.54) | FABP3FABP4MDM2CMKLR1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | claimed |
| EP-1663105-A4 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-15 | — | — | EP | claimed |
| JP-2007505114-A | — | — | 2007-03-08 | — | — | JP | claimed |
| US-7112601-B2 | Cycloalkyl heterocycles for treating hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-26 | — | — | US | claimed |
| EP-1663105-A2 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | Bristol-Myers Squibb Company (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005034850-A2 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | claimed |
| US-20050075376-A1 | Cycloalkyl heterocycles for treating Hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-07 | — | — | US | claimed |
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | disclosed |
| EP-1663105-A4 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-15 | — | — | EP | disclosed |
| US-7112601-B2 | Cycloalkyl heterocycles for treating hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1663105-A2 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | Bristol-Myers Squibb Company (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005034850-A2 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050075376-A1 | Cycloalkyl heterocycles for treating Hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075376-A1 | Cycloalkyl heterocycles for treating Hepatitis C virus | HCCS, NSUN2, HAVCR2 | FABP3 3457/4885FABP4 4331/4885FFAR1 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.